Table 1.
Summarized results of a preclinical experiment testing the effect of MK-2206 treatment on Brca1-mutant tumors
| Treatment | RTV2 at 3 W | Survival (W) | SAE3 | DCR4 |
|---|---|---|---|---|
| Not Treated | 5.77±1.22 | 3.80±0.45 | 0/5 | 0/5 |
| MK-2206 | 2.79±1.80** | 7.77±2.68** | 2/11 | 10/11 |
| Olaparib | 3.98±3.04 | 4.65±3.87 | 5/10 | 3/10 |
| Combination | 1.79±1.06** | 4.00±2.91 | 8/11 | 9/11 |
1The numbers represent mean±SD, with significant differences indicated by asterisks (**P<0.01); 2RTV, ratio of tumor volume after treatment versus baseline (at inception of treatment); 3SAE, serious adverse effect; 4DCR, disease control rate